POTENTIATION OF PIRARUBICIN CYTOTOXICITY BY DIPYRIDAMOLE IN DOXORUBICIN-RESISTANT MOUSE P388 LEUKEMIA-CELLS

被引:0
|
作者
FURUSAWA, S
FUJIMURA, T
KAWAUCHI, H
SASAKI, K
TAKAYANAGI, Y
机构
关键词
D O I
暂无
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
The activity of dipyridamole and its possible mechanisms which reverse the resistance to pirarubicin were studied in a P388 mouse leukemia cell lines. Dipyridamole alone was minimally cytotoxic in both of the doxorubicin-resistant cell line (P388/DOX) and the sensitive parent cell line (P388/S), but reversed pirarubicin-resistance in a dose-related manner in P388/DOX cells. A similar dose-response relationship was observed for dipyridamole by increasing net intracellular pirarubicin accumulation. The increase was a result of secondary blocking of enhanced pirarubicin efflux from P388/DOX cells. In contrast, dipyridamole did not affect cytotoxicity and transport in the drug-sensitive cell line. It is suggested that dipyridamole is a useful drug for modulation of the multidrug-resistance of cells.
引用
收藏
页码:321 / 336
页数:16
相关论文
共 50 条
  • [31] ELECTROPHORETIC MOBILITY STUDIES ON DOXORUBICIN-RESISTANT AND DOXORUBICIN-SENSITIVE MURINE P388 LEUKEMIC-CELLS
    NAIR, S
    HORTON, A
    LEIF, RC
    KRISHAN, A
    CYTOMETRY, 1988, 9 (03): : 232 - 237
  • [32] PLASMA-MEMBRANE LIPID STRUCTURAL ORDER IN DOXORUBICIN-SENSITIVE AND DOXORUBICIN-RESISTANT P388 CELLS
    RAMU, A
    GLAUBIGER, D
    MAGRATH, IT
    JOSHI, A
    CANCER RESEARCH, 1983, 43 (11) : 5533 - 5537
  • [33] Effects of Dex-Verapamil on Doxorubicin cytotoxicity in P388 murine leukemia cells
    Noviello, E
    Allievi, E
    Russo, P
    Parodi, S
    ANTI-CANCER DRUG DESIGN, 1997, 12 (04): : 261 - 276
  • [34] POTENTIATION OF THE VINCRISTINE EFFECT ON P388 MOUSE LEUKEMIA-CELLS BY A NEWLY SYNTHESIZED DIHYDROPYRIDINE ANALOG, PAK-200
    SHUDO, N
    FUJII, R
    MATSUMOTO, T
    MIZOGUCHI, T
    SETO, K
    SAKODA, R
    AKIYAMA, S
    JAPANESE JOURNAL OF CANCER RESEARCH, 1992, 83 (09): : 1011 - 1017
  • [35] REVERSAL OF RESISTANCE BY N-ACETYLTYRAMINE OR N-ACETYL-2-PHENYLETHYLAMINE IN DOXORUBICIN-RESISTANT LEUKEMIA P388 CELLS
    KUNIMOTO, S
    XU, CZ
    NAGANAWA, H
    HAMADA, M
    MASUDA, T
    TAKEUCHI, T
    UMEZAWA, H
    JOURNAL OF ANTIBIOTICS, 1987, 40 (11): : 1651 - 1652
  • [36] DIFFERENTIAL ALTERATION OF CELLULAR LIPIDS IN DRUG SENSITIVE AND RESISTANT P388 LEUKEMIA-CELLS BY CLOFIBRATE - EFFECTS ON MITOXANTRONE CYTOTOXICITY
    PAREKH, H
    CHITNIS, M
    TUMORI JOURNAL, 1991, 77 (02): : 105 - 111
  • [37] CALMODULIN INHIBITOR TRIFLUOPERAZINE SELECTIVELY ENHANCES CYTO-TOXIC EFFECTS OF STRONG VS WEAK DNA-BINDING ANTITUMOR DRUGS IN DOXORUBICIN-RESISTANT P388 MOUSE LEUKEMIA-CELLS
    GANAPATHI, R
    GRABOWSKI, D
    SCHMIDT, H
    SESHADRI, R
    ISRAEL, M
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1985, 131 (02) : 912 - 919
  • [38] POTENTIATION OF ADRIAMYCIN CYTOTOXICITY IN P388 MURINE LEUKEMIA SENSITIVE AND RESISTANT TO ADRIAMYCIN BY USE OF LONIDAMINE AND HYPERTHERMIA
    CHITNIS, M
    ADWANKAR, M
    TUMORI, 1986, 72 (05) : 469 - 473
  • [39] GLUTATHIONE S-TRANSFERASES AND GLUTATHIONE PEROXIDASES IN DOXORUBICIN-RESISTANT MURINE LEUKEMIC P388 CELLS
    SINGH, SV
    NAIR, S
    AHMAD, H
    AWASTHI, YC
    KRISHAN, A
    BIOCHEMICAL PHARMACOLOGY, 1989, 38 (20) : 3505 - 3510
  • [40] EVALUATION OF NEW ANTHRACYCLINES ON P388-LEUKEMIA SENSITIVE (P388/S) OR RESISTANT (P388/R) TO DOXORUBICIN (DX)
    GERONI, CM
    PODESTA, A
    BARBIERI, BM
    GIULIANI, FC
    CASAZZA, AM
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1983, 24 (MAR): : 280 - 280